Moderna and Pfizer see revenue decline due to low demand for their COVID-19 vaccines.

Moderna forecasts its 2023 revenue will reach $6 billion, lower than the $6-8 billion the company had previously projected.

Photo: Reuters

However, Moderna believes sales will rebound in 2025, driven by forecasts that the US will purchase at least 50 million doses of its COVID-19 vaccine.

In 2024, Moderna expects to generate $4 billion in revenue from the sale of its Spikevax COVID-19 vaccine and its respiratory syncytial virus (RSV) vaccine.

Currently, Pfizer is also suffering significant losses due to sluggish sales of its COVID-19-related products. According to the report, the company lost $2.4 billion in the third quarter of 2024, while in the same period last year, it recorded a profit of $8.6 billion.

This loss is due to the company still having a large inventory of COVID-19 vaccines and treatments worth up to $5.6 billion.

Hoang Nam (according to Reuters)

Source: https://www.congluan.vn/moderna-va-pfizer-sut-giam-doanh-thu-do-e-am-vac-xin-covid-19-post271013.html